The U.S. Food and Drug Administration (FDA) has granted orphan drug exclusivity for Octapharma’s wilate, von Willebrand factor/coagulation factor VIII complex (human) lyophilized powder for solution for intravenous injection, for routine prophylaxis to reduce the frequency of bleeding episodes in adults and children 6 years of age and older with von Willebrand disease (VWD).
Through regulatory pathways and patient engagement, FDA is helping to advance treatment innovations for rare diseases.
Does the shorter preparation time for fibrinogen concentrates make them a reasonable option in lieu of IFC in defined patient populations experiencing massive hemorrhage?
Post-pandemic America is facing a mental health crisis, but collaboration and creativity in healthcare aim to improve the nation’s mental wellness.
Enrolling patients in clinical trials is a slow and costly process, but software companies are working to address the problem.
While agencies race to put in place regulations for using artificial intelligence to reduce the spread of health misinformation, healthcare providers can help to correct this by engaging with their patients.
Sleep disorders are responsible for a host of physical and mental health conditions, making it essential to dispel the myths surrounding them and to promote education and awareness about the importance of sleep health.
While malaria is no longer endemic in the United States, the mosquito-borne disease can still affect those who live in or travel to tropical areas of the globe.
Patient safety is at the heart of healthcare, so it’s imperative to put in place systems and regulations to reduce patient harm.
Though mostly benign, this bothersome skin disease could be dangerous for those with a compromised immune system. But while an effective, FDA-approved treatment specially formulated for the highly contagious poxvirus has eluded the disease — that's no longer the case.
Numerous studies show the efficacy of both IVIG and SCIG for treating CIDP, making these the best treatment options for this rare neurological condition.
The effectiveness of this controversial therapy in treating musculoskeletal disorders and other arthritic conditions is uncertain due to mixed results. Nevertheless, the PRP industry is booming.
